Ridinilazole, a narrow spectrum antibiotic for treatment of Clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids

• Published in: American journal of physiology: Gastrointestinal and liver physiology Vol. 319; no. 2; pp. G227 - G237
• Main Authors: Qian, Xi, Yanagi, Karin, Kane, Anne V., Alden, Nicholas, Lei, Ming, Snydman, David R., Vickers, Richard J., Lee, Kyongbum, Thorpe, Cheleste M.
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.08.2020
• Series: Microbiome and Host Interactions
• Subjects: Acids; Anti-Bacterial Agents - pharmacology; Antibiotics; Benzimidazoles - pharmacology; Bile; Bile acids; Bile Acids and Salts - chemistry; Bile Acids and Salts - metabolism; Clostridiales - drug effects; Correlation analysis; Digestive system; Dysbacteriosis; Feces - chemistry; Gastrointestinal Microbiome - drug effects; Gastrointestinal Microbiome - physiology; Gastrointestinal tract; Humans; Infections; Intestinal microflora; Intestine; Microbiota; Preservation; Pyridines - pharmacology; Risk factors; Vancomycin; longitudinal outcome; Clostridioides difficile infection; antibiotic therapy; bile acid

This is the first study to demonstrate in humans the relationships between Clostridioides difficile antibiotic treatment choice and bile acid metabolism both during therapy and after treatment cessation. The results show a microbiota- and metabolome-preserving property of a novel narrow-spectrum age...